SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
SINOVAC BIOTECH LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026
$6.47+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 850.08%
Share price
$0.00 (0.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
SINOVAC BIOTECH LTD grew revenue 6.8% to $386.01M over fiscal 2025. Free cash flow was -$561.10M.
Revenue
$386.01M
+6.8% vs. a year earlier
Operating income
-$490.13M
FY2025
Free cash flow
-$561.10M
FY2025
EPS, diluted
-$0.83
-165.4% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 850.08%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $386.01M
- EPS, diluted
- -$0.83
- Free cash flow
- -$561.10M
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
$386.01M+6.8% YoY
Gross profit
$261.98M+18.7% YoY
Operating income
-$490.13M
Net income
–
EPS, diluted
-$0.83-165.4% YoY
Free cash flow
-$561.10M
Reported period